04 March 2022>: Articles
Dramatic Response to Trastuzumab Deruxtecan Rechallenge in a Patient with HER2-Positive Gastric Cancer: A Case Report
Unusual setting of medical care
Takatsugu Ogata A , Yasuko Fujita B , Kei Muro A*DOI: 10.12659/AJCR.935600
Am J Case Rep 2022; 23:e935600
Figure 1. Computed tomography scans. (A) Before the rechallenge with trastuzumab deruxtecan (T-DXd), wall thickening in the cardia of stomach was observed; the length of the stomach wall was 29.3 mm. (B) After 3 cycles of T-DXd, shrinkage of the primary tumor was observed; the length of the stomach wall was 16.0 mm. (C) After 7 cycles of T-DXd, shrinkage of the primary tumor was observed; the length of the stomach wall was 11.8 mm.